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Abstract
Background: Cancer progression is closely linked to the epithelial-mesenchymal transition (EMT) process. Studies
have shown that there is increased expression of tissue tranglutaminase (TG2) in advanced invasive cancer cells.
TG2 catalyzes the covalent cross-linking of proteins, exhibits G protein activity, and has been implicated in the
modulation of cell adhesion, migration, invasion and cancer metastasis. This study explores the molecular
mechanisms associated with TG2’s involvement in the acquisition of the mesenchymal phenotype using the highly
invasive A431-III subline and its parental A431-P cells.
Results: The A431-III tumor subline displays increased expression of TG2. This is accompanied by enhanced
expression of the mesenchymal phenotype, and this expression is reversed by knockdown of endogenous TG2.
Consistent with this, overexpression of TG2 in A431-P cells advanced the EMT process. Furthermore, TG2 induced
the PI3K/Akt activation and GSK3b inactivation in A431 tumor cells and this increased Snail and MMP-9 expression
resulting in higher cell motility. TG2 also upregulated NF-B activity, which also enhanced Snail and MMP-9
expression resulting in greater cell motility; interestingly, this was associated with the formation of a TG2/NF-B
complex. TG2 facilitated acquisition of a mesenchymal phenotype, which was reversed by inhibitors of PI3K, GSK3
and NF-B.
Conclusions: This study reveals that TG2 acts, at least in part, through activation of the PI3K/Akt and NF-B
signaling systems, which then induce the key mediators Snail and MMP-9 that facilitate the attainment of a
mesenchymal phenotype. These findings support the possibility that TG2 is a promising target for cancer therapy.
Keywords: epithelial-mesenchymal transition, tissue transglutaminase, matrix metalloproteinase, PI3K/Akt, NF-?κ?B,
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Background
The epithelial-mesenchymal transition (EMT), first
recognized as a hallmark of embryogenesis in the early
1980, is a crucial morphogenic process during embryo-
nic development [1,2]. During the EMT, the non-motile
polarized epithelial cells that originally display many
cell-cell junctions lose contact with each other and gra-
dually convert into individual, non-polarized, motile,
and invasive mesenchymal cells [3]. There is growing
acceptance that the detachment of single carcinomatous
cells and their migration into the stroma replicates the
developmental EMT process [4-6]. The EMT is a
vibrant, dynamic and transient process, and therefore
the process manifests as epithelial cell plasticity during
tumor progression. A striking characteristic of the EMT
is the loss of E-cadherin expression, an important care-
taker of the epithelial phenotype [1]. Several transcrip-
tion factors have been implicated in the transcriptional
repression of E-cadherin, including the zinc finger pro-
teins of the Snail/Slug family, Twist, δEF1/ZEB1, SIP1,
and the basic helix-loop-helix factor E12/E47 [4,7].
These repressors also act as molecular triggers of the
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that encode cadherins, claudins, cytokines, integrins,
mucins, plakophilin, occludin, and zonula occludens
proteins, thereby promoting EMT. All of these tran-
scription factors have been duly recognized as playing a
critical role in cell survival, differentiation, and
metastasis.
Tissue transglutaminase (TG2/tTG), a member of the
transglutaminase family, is a calcium-dependent enzyme
that catalyzes the covalent cross-linking of proteins.
This multifunctional protein is expressed ubiquitously
and abundantly, and has been implicated in a variety of
cellular processes, such as cell differentiation, death,
inflammation, migration, and wound healing [8-12].
Patients suffering from cancers may become refractory
to anticancer agents (drug resistance) following che-
motherapy or undergo cancer cell metastasis. Research-
ers have noticed that cancer cells exhibiting resistance
to anticancer drugs together with those that are isolated
from metastatic sites have relatively higher TG2 expres-
sion levels [13-16]. Additionally, down-regulation of
TG2 by gene-specific siRNA, antisense RNA or ribo-
zyme approaches reverses drug-resistance in breast, pan-
creatic, lung, and ovarian carcinoma cells [17-22].
Recently, Shao and coworkers documented that TG2
modulated the EMT and contributed to increased ovar-
ian cancer cell invasiveness and tumor metastasis [23].
They showed that TG2 induced Zeb1 by activating the
NF-B complex. The effects of TG2 on ovarian cancer
cell phenotype and invasiveness translated into increased
metastasis and tumor formation in vivo, as assessed in
an orthotopic ovarian xenograft model. Kumar and cow-
orkers also have shown that aberrant expression of TG2
is sufficient to induce the EMT in epithelial cells, and
they also established a strong link between TG2 expres-
sion and progression of metastatic breast disease [24].
The nature of TG2 involvement in the EMT has not
been well elucidated. Nevertheless, the above studies
provide evidence implying that TG2 promotes EMT and
enhances tumor metastasis by activating oncogenic
signaling.
We have isolated a highly invasive tumor cell subline
(A431-III) from parental A431 tumor cells (A431-P)
using a Boyden chamber system with matrigel-coated
membrane support. These A431-III cells secrete a
higher level of MMP-9 and exhibit greater adhesion,
spreading, migration, and invasive capability compared
to A431-P cells [25]. Based on the above, A431-P cells
and A431-III subline should be able to serve as a model
system that will help to delineate the mechanisms
involved in the EMT. We observed that MMP-9-
induced acquisition of an invasive phenotype in A431-
III cells was associated with marked and decisive
increases in the levels of fibronectin and TG2 [26]. In
addition, our most recent study produced an interesting
finding whereby MMP-9 and Snail form a mutual regu-
latory loop, and work cooperatively within the EMT
induction process [27]. Since highly invasive A431-III
cells display enhanced expression of TG2 [26], and TG2
expression modulates the EMT [23,24], we were
prompted to explore the role of TG2 in the induction of
the EMT in A431-P and A431-III cells.
I nt h i ss t u d yw eh a v ed e m o n s t r a t e dt h a tT G 2p a r t i c i -
pates in the acquisition of the mesenchymal phenotype
in A431-P and A431-III cells. We propose that TG2,
acting via activation of NF-B and PI3K/Akt-GSK3b sig-
naling, enhances the expression of Snail, and that this
leads to the acquisition of mesenchymal phenotype in
A431-III cells. This in turn promotes MMP-9 activity,
which increases cancer cell motility and metastatic
potential. This and other studies support the contention
that TG2 is a promising therapeutic target for studies
that explore reversing drug resistance and inhibiting the
metastatic potential of tumor cells.
Methods
Materials
The A431 tumor cell line was obtained from the Ameri-
can Type Culture Collection (ATCC; Manassas, VA).
The epidermoid carcinoma cell line A-431 was origin-
ally derived from a cervical solid tumor of an 85-year-
old female [28]. TG2 siRNA, and non-specific siRNA
were purchased from Invitrogen (Carlsbad, CA). Anti-
TG2 was purchase from Thermo Scientific (Fremont,
CA). Anti-Snail was obtained from Abcam (Cambridge,
MA) and anti-N-cadherin was purchased from Abgent
(San Diego, CA). Anti-fibronectin and anti-b-actin were
purchased from Sigma (St. Louis, MO). Anti-vimentin
(V9) and anti-IBa were obtained from Santa Cruz
(Santa Cruz, CA). Anti-p-Akt(Ser473), anti-p-GSK3b
(Ser9), anti-Lamin A, and anti-cyclin D1 were obtained
from GeneTex (Irvine, CA). Anti-Akt was obtained
from Cell Signaling (Boston, MA). Anti-NF-Ba n d
anti-GSK3bwere obtained from BD Transduction
(Franklin Lakes, NJ). All PCR forward and reverse pri-
mers were purchased from Purigo Biotech (Taipei,
Taiwan).
Preparation of cell lysates and nuclear extracts
The cells were lysed in gold lysis buffer, containing 20
mM Tris-HCl (pH 7.9), 1 mM EGTA, 0.8% NaCl, 0.1
mM b-glycerylphosphate, 1 mM sodium pyrophosphate,
10 mM NaF, 1 mM Na4P2O7,1m MN a 3VO4,1 0 %g l y -
cerol, 1% Triton X-100, 1 mM PMSF, 10 μg/ml aproti-
nin, and 10 μg/ml leupeptin. Insoluble material was
separated by centrifugation at 14,000 × g for 20 min at
4°C. Protein concentrations were determined using the
method of Bradford [29].
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formed as described by Schreiber et al. [30]. Briefly, the
cell pellets were resuspended in 400 μLo fb u f f e rA ,
containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1
mM EDTA, 0.1 mM EGTA, 1 mM DTT, PMSF 1 mM.
The cells were incubated on ice 15 min and then 25 μL
of 10% NP-40 was added. The cells were centrifuged at
500 × g for 5 min. The supernatant, which contains the
cytoplasmic fraction, was then collected. The nuclear
pellet was resuspended in 50 μLo fc o l db u f f e rB ,c o n -
taining 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF. The
vials then rocked vigorously on a shaking platform for
15 min, which was followed by centrifugation at 500 × g
for 5 min. The supernatant nuclear fraction was then
collected.
Western blotting
Protein samples were separated on 10% SDS-polyacryla-
mide gels. The membrane blots were blocked in PBS
containing 5% BSA for 1 h at room temperature, and
incubated with primary antibody overnight at 4°C. After
washing with TBST containing 20 mM Tris-HCl (pH
7.6), 0.8% (w/v) NaCl, and 0.25% Tween-20, the blots
were incubated with secondary antibody conjugated with
horseradish peroxidase. The immunoreactive bands were
detected with ECL reagents (Millipore, Billarica, MA)
and exposed using Fujifilm (Tokyo, Japan). The relative
quantification of the ECL signals on the X-ray film was
carried out by Image J software (NIH, Bethesda, MD).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated using a PureLink RNA Mini Kit
(Invitrogen, Carlsbad, CA), and reverse transcribed
using a MMLV High Performance Reverse Transcriptase
kit (Epicentre, Madison, WI). PCR amplication was per-
formed over 20-40 cycles that consisted of denaturation
at 94°C for 30s, annealing at 55°C to 60°C for 30s, and
extension at 72°C for 30s-60s. Forward and reverse pri-
mers for the gene cDNA amplification are listed in the
Table 1. The PCR products were separated on 1% agar-
ose gels, stained with SYBR safe DNA stain (Invitrogen),
and visualized under UV light.
Gene construction and transfection
The full length cDNA encoding TG2 was isolated from
human cervical epithelial cancer cell A431-III cDNA by
RT-PCR using the specific primers, hTG2-F, 5’-
AGGAGCCACCGCCCCCGCCCGACCATGGCC-3’ and
hTG2-R, 5’-CAGCAGGCTGGGAGCAGGGGTCCCT-
TAGGC-3’. The full length of TG2 was then cloned
into the pGEMT-Easy vector (Promega, San Luis
Obispo, CA) and identified by DNA sequencing. The
coding region of TG2 was removed from the pGEMT-
Easy vector using the restriction enzymes EcoRI and
XhoI, and then subcloned into the EcoRI and XhoI sites
of the pcDNA3.1 vector. Ligation of the restriction
enzyme digested TG2 and pcDNA3.1 vector generated
pcDNA3-TG2.
A431-P cells were seeded into 6-cm cultured dishes
and then transfected with 4 μgo fp c D N A 3 - T G 2u s i n g
the Xfect transfection reagent (Clontech, Mountain
View, CA) following the manufacturer’s instructions.
Expression of TG2 was screening by Western blotting
and RT-PCR.
Transfection of small interfering RNA (siRNA)
TG2 siRNA and non-specific siRNA were dissolved in
RNase-free water provided by the manufacturer to a
stock concentration of 20 μM. A431-P and A431-III
cells were plated into 60 mm culture dishes and then
transfected with 40 nM of siRNA using lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA) fol-
lowing the manufacturer’s instructions. All assays were
performed 48 h after transfection.
NF-B reporter luciferase assay
A431-P and A4331-III cells were seeded into 6-well
plates. The cells were transfected with 2.5 μgo fp N F -
B-Luc (Panomics, Dumbarton Circle Fremont, CA) or
empty control vector using Xfect transfection reagent
(Clontech), following the manufacturer’si n s t r u c t i o n s .
To detect the luciferase activity, the cells were lysed in
luciferase cell-culture lysis reagent (Promega) and 50 μL
of cell lysate was then mixed with 50 μL of luciferase
assay substrate. The relative light units produced by
each sample were detected by 1420 Luminescence
Counter (Perkin Elmer, Waltham, MA). The sample
data were normalized against the empty vector control
and the protein concentrations.
Gelatin zymography
Samples of conditioned media were subjected to electro-
phoresis on 8% SDS-polyacrylamide gels copolymerized
with 0.1% gelatin. The volume of each medium sample
Table 1 The forward and reverse primers of genes
Gene
Name
Forward and Reverse primers Amplified size
(bps)
MMP-9 F 5’-TCTTCCCTGGAGACCTGAGAAC-3’ 428
R5 ’-GACACCAAACTGGATGACGATG-3’
Snail F 5’-GCTCCTTCGTCCTTCTCCTCTA-3’ 390
R5 ’-GGCACTGGTACTTCTTGACA-3’
TG2 F 5’-GGAGGATATCACCCACACCTACA-3’ 361
R5 ’-CGTAAGGCAGTCACGGTATTTC-3’
GAPDH F 5’-CCATCACTGCCACCCAGAAGA-3’ 439
R5 ’-TCCACCACCCTGTTGCTGTA-3’
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After electrophoresis, the gels were washed for 60 min
in 2.5% Triton X-100, and incubated in reaction buffer
(50 mM Tris-HCl, pH 8.0, containing 5 mM CaCl2,a n d
0.02% NaN3)a t3 7 ° Cf o r2 4h .T h eg e l sw e r et h e n
stained with Coomassie Blue R-250 in 10% acetic acid/
20% ethanol for 1 h, followed by destaining in the same
solution without dye. A clear zone on the gel indicated
the presence of gelatinase activity, which was then quan-
tified by densitometry.
Immunofluorescence staining
A431-P and III cells were plated into 6-well plates con-
taining glass coverslips without a fibronectin coating.
Following treatment with TG siRNA and non-specific
siRNA, or following transfection with the TG2 expres-
sion vector, the cells were fixed with 4% paraformalde-
hyde. Cells were permeabilized with 0.1% Triton X-100
in PBS for 10 min. The permeabilized cells were then
incubated with 3% BSA in PBS to block non-specific
binding for 1 h at room temperature. After thorough
rinsing with PBS, the cells were incubated with mouse
monoclonal anti-vimentin and rabbit polyclonal anti-
fibronectin antibodies at 4°C overnight. Next the cells
were incubated with fluorescently labeled secondary
antibodies for 1 h at room temperature in the dark.
After rinsing with PBS, the cells were then stained with
DAPI in PBS for 5 min at room temperature. The cov-
erslips were then mounted using mounting medium on
microslides and visualized by confocal microscopy.
In vitro wound-healing migration assay
Both A431 and A431-III cells transfected with either
TG2 siRNA or the full length TG2 expression vector
were plated onto six-well culture plates in RPMI-1640
containing 10% FBS. After 24 h, the cell monolayers
were wounded by manually scratching it with a pipette
tip; this was followed by washing with PBS. The mono-
layers were then incubated at 37°C for 24 h. The mono-
layers were photographed at 0 h and 24 h after
wounding using phase contrast microscopy and an
Olympus IX70 camera. The experiments were per-
formed in triplicate for each treatment group.
Statistical analysis
The quantitative data derived from three to six indepen-
dent experiments are expressed as means (± SEM).
Unpaired Student’s t-tests were used to analyze between
group differences that is repeated and p < 0.05 was con-
sidered statistically significant.
Results
Previously, we have demonstrated that TG2 and fibro-
nectin are both upregulated in the highly invasive A431-
III subline compared with the parental A431-P cells,
and that knockdown of TG2 decreased integrin’s asso-
ciation with fibronectin as well as reducing the level of
MMP-9 and MMP-1; these events were accompanied by
a reduction the A431-III cells’ capability of undergoing
adhesion, migration and invasion [26]. This prompted
us to further explore the potential role of TG2 in the
modulation of the EMT as well as the associated
mechanisms using the A431-P and A431-III system that
had been established in our laboratory.
TG2 modulation of various EMT markers in A431-P and
A431-III cells
To understand whether TG2 plays a role in the induc-
tion of the EMT process in A431 cells, we employed
two experimental approaches. The first involved the
transfection of TG2 siRNA into A431-P and A431-III
cells. We found that knockdown of endogenous TG2
resulted in the reduced expression of various mesenchy-
mal markers, namely fibronectin, vimentin, N-cadherin,
and Snail (a key transcriptional repressor promoting
EMT process). This knockdown had a greater effect on
the A431-III subline than on A431-P cells as was shown
by immunoblotting and confocal microscopy analysis
(Figures 1A &1B). In addition, and consistent with our
previous study [26], knockdown of TG2 decreased the
expression and activity of MMP-9, and this reduced the
cells’ migratory activity; these finding were obtained by
RT-PCR, gelatin zymography and in vitro wound healing
assays, respectively (Figures 1C to 1E).
Next, we used the alternative approach of over-expres-
sing TG2 in A431-P cells that show a naturally low level
of TG2 (Figure 1A) by transfection with full-length TG2
(pcDNA3.1-TG2). A431-P cells normally produce com-
pact clusters of cells in culture, and these clusters
became more scattered and fibroblastic in nature follow-
ing TG2 over-expression (Figure 2A). These changes
were accompanied by increased expression of various
mesenchymal markers, fibronectin, vimentin, N-cadherin
and Snail (Figures 2B &2C). Additionally, the A431-P
cells over-expressing TG2 showed an increased expres-
sion of MMP-9 as well as displaying enhanced migratory
potential (Figures 2D &2E). Collectively, these results
suggest that TG2 induces the acquisition of an EMT-
like phenotype in A431-P and A431-III cells.
Involvement of PI3K/Akt-GSK3 signaling in the TG2-
facilitated EMT process
Recent studies have demonstrated that activation of
PI3K/Akt-GSK-3b signaling may induce the EMT pro-
cess, a loss of cell-to-cell adhesion and cell polarity,
morphological changes, an induction of cell motility,
and decreased cell-matrix adhesion [31]. GSK-3b,au b i -
quitously expressed protein serine kinase, is active in
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activity or its expression may lead to the EMT [33]. We
t h e r e f o r ew e r ei n t e r e s t e dt oe x p l o r et h er o l eo fP I 3 K /
Akt- GSK-3b signaling in the TG2-facilitated EMT pro-
cess in A431 cells. We first examined Akt and GSK-3b
activity and their relationship with TG2. A431-III cells
showed a relatively higher level of phosphorylated Akt-
S473 (activation) and an increased level of phosphory-
lated GSK-3b- S 9( i n a c t i v a t i o n )w h e nc o m p a r e dw i t h
A431-P cells (Figure 3A). In addition, knockdown of
TG2 resulted in decreased Akt activity and increased
GSK-3b activity in A431-III cells (Figure 3A).
Next, we examined the potential involvement of PI3K/
Akt-GSK3 signaling in the EMT using specific inhibitors
of PI3K (LY294002) and GSK-3b (SB415286). Treatment
of A431-III cells with LY294002 reduced the level of
Snail and secreted MMP-9, and this was accompanied
by reduced cell motility (Figures 3B to 3D). In parallel,
treatment of A431-P cells with SB415286 increased the
expression of Snail and MMP-9, as well as promoting
Figure 1 Effect of TG2 knockdown on mesenchymal markers in A431-P and A431-III cells. (A) The cells were treated with 40 nM of TG2-
specific siRNA or control siRNA. At 48 h post-transfection, cell lysates were prepared and subjected to immunoblotting analysis for TG2, Snail
fibronectin, N-cadherin, vimentin and b-actin served as internal controls. (B) The cells were plated onto non-fibronectin-coated cover slips in six-
well plate for 24 h. The cells were treated with 40 nM of TG2 siRNA or control siRNA, and then immuno-stained for fibronectin (green) and
vimentin (red) with the nuclei stained with DAPI (blue). The fluorescence images were visualized using confocal microscopy. (C) Total RNA was
extracted at 48 h after siRNA transfection and analyzed for TG2, Snail and MMP-9 by RT-PCR with GAPDH served as the internal control. (D) The
culture conditioned media of TG2-silenced cells were collected and normalized by cell numbers prior to gelatin zymography analysis. (E) After
TG2 knockdown, a wound healing assay was performed by scratching the cell layer with a pipette tip, and phase-contrast images were taken at
0 h and 24 h later to assess cell migration into the open space. Quantitative data are presented as the mean (± SD) percentage of migration
distance (n = 20). * and # indicate a significant difference compared with the respective control (p< 0.05).
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Page 5 of 13Figure 2 Effect of TG2 over-expression on mesenchymal-like phenotype in A431-P cells. (A) Phase-contrast images of empty vector
(pcDNA3.1) or full length TG2 (pcDNA3.1-TG2)-transfected cells cultured on six-wells plates in culture medium containing 10% FBS (×100
magnification). At 48 h post-transfection, (B) cell lysates were prepared and subjected to immunoblotting analysis for TG2, Snail, fibronectin, N-
cadherin, and vimentin. (C) Cells were immuno-stained for fibronectin (green) and vimentin (red) as well as having DAPI (blue) staining of the
nuclei. The fluorescence images were visualized by confocal microscopy. (D) Total mRNA was extracted and analyzed for TG2, Snail and MMP-9
by RT-PCR. (E) Cell migratory activity was determined using the wound healing assay as described in figure 1. Quantitative data are presented as
the mean (± SD) percentage of migration distance (n = 20). * indicates a significant difference compared with the control (p< 0.05).
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Page 6 of 13cell motility (Figures 4A to 4C). Cyclin D was used as a
p o s i t i v ec o n t r o la si ti ss u b j e c tt oG S K - 3 b-dependent
proteolysis [34]. To further ascertain the involvement
PI3K/Akt-GSK-3b signaling in the TG2-induced acquisi-
tion of the mesenchymal phenotype, we used the alter-
native approach of transfecting pcDNA3.1-TG2 into
A431-P cells. TG2-overexpresson in A431-P cells
resulted in increased Akt activity and attenuated GSK-
3b activity, and these effects were abrogated by treat-
ment with the PI3K inhibitor LY294002 (Figures 4D). In
a similar manner to that observed for A431-III cells,
treatment of TG2-overexpressing A431-P cells with
LY294002 reduced the level of Snail and secreted MMP-
9, as well as reducing cell motility (Figures 4D to 4F).
These results together suggest that the TG2 induced-
acquisition of an EMT-like phenotype by the highly
invasive A431-III subline involves an activation of PI3K/
Akt signaling and an inactivation of GSK-3b.
Involvement of NF-B signaling in TG2-facilitated EMT
process
Wirth et al. identified NF-B as a central mediator of
the EMT in a mouse model of breast cancer progression
[35]. In order to elucidate the role of NF-B signaling in
the TG2-facilitated EMT process in A431 cells, we con-
ducted experiments using three approaches. The first
was to examine NF-B activity and its relationship with
EMT. When compared to A431-P cells, the A431-III
subline, which exhibits relatively high TG2 expression,
showed a markedly reduced level of IBa (an endogen-
ous inhibitor of NF-B), and an increased nuclear level
of NF-B relative to a similar total cellular level of NF-
Figure 3 Positive association of PI3K/Akt-GSK-3b signaling activation with the EMT phenotype in A431-P and A431-III cells. (A) Cells
were treated with 40 nM of control or specific TG2 siRNA. Cellular activity of Akt and GSK-3b were determined by analyzing their
phosphorylation status using immunoblotting. (B-D) Cells were treated with 20 μM Akt inhibitor LY294002 for 24 h. (B) The cellular protein and
RNA levels of Snail were respectively determined by immunoblotting and RT-PCR. (C) The secreted activity of MMP-9 was measured using
gelatin zymography. (D) Cell migratory activity was determined by wound healing assay. Quantitative data are presented as the mean (± SD)
percentage of migration distance (n = 20). * indicates a significant difference compared with the respective control (p< 0.05). # indicates a
significant difference compared with the A431-P (p < 0.05).
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we found that NF-B activity was significantly increased
in A431-III cells, and this was suppressed by treatment
with an NF-B inhibitor, JSH-23 (Figure 5B). The
increased NF-B activity in A431-III cells was positively
correlated with the increased nuclear level of TG2 (Fig-
ure 5A), and an increased association of TG2 with
NFB (Figure 5C). Additionally, treatment with JSH-23
reduced the level of Snail, secreted MMP-9 activity and
the A431-III subline migratory activity (Figures 5D to
5F), which suggests the potential involvement of NF-B
in the EMT process.
Next, we explored the effect of TG2 siRNA transfec-
tion on A431-P and A431-III cells. Knockdown of TG2
Figure 4 Upregulation of PI3K/Akt-GSK-3b signaling activation is associated with the EMT phenotype in TG2-overexpressing A431-P
cells. (A-C) The cells were treated with 25 μM of the specific GSK3 inhibitor SB415286 for 48 h. (A) The cellular protein and RNA levels of Snail
and MMP-9 were respectively determined by immunoblotting and RT-PCR. Cyclin D served as the indicator of the inhibition of GSK-3b activity.
(B) The secreted MMP-9 activity was detected using gelatin zymography. (C) Cell migratory activity was determined by the wound healing assay.
Quantitative data are presented as the mean (± SD) percentage of migration distance (n = 20). (D-F) A431-P cells were transfected with empty
pcDNA3.1 vector or pcDNA3.1-TG2, and then treated with 20 μM of PI3K inhibitor LY294002 for 24 h. (D) Cell lysates were analyzed for
phosphorylated Akt, GSK-3b, Snail and TG2 using immunoblotting. (E) The secreted activity of MMP-9 was detected by gelatin zymography. (F)
Cell migratory activity was determined using the wound healing assay. Quantitative data are presented as the mean (± SD) percentage of
migration distance (n = 20). * indicates a significant difference compared with the respective control (p< 0.05). # indicates a significant difference
compared with the A431-P (p < 0.05).
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Page 8 of 13Figure 5 Positive association of GSK-3b activity with TG2 and the EMT phenotype in A431-P and A431-III cells. (A) Total cell lysates and
cytosolic and nuclear extracts were prepared and analyzed for TG2, NF-B, and IBa by immunoblotting. (B) Cells were treated with 25 μMo f
JSH-23 for 24 h, and the cellular NF-B of activity was determined using a luciferase reporter assay. (C) The interaction of TG2, NF-B, and IBa
in A431-P and the A431-III sub-line. (D-E) Cells were treated with 20 or 25 μM of JSH-23 for 24 h, and cell lysates were analyzed for Snail by
immunoblotting, and the conditioned media was analyzed for MMP-9 activity by gelatin zymography. (F) Cells were treated with 25 μM of JSH-
23 for 24 h, and analyzed for migratory activity using wound healing assay. Quantitative data are presented as the mean (± SD) percentage of
migration distance (n = 20). (G) Cells were transfected with control or specific TG2 siRNA, and cellular NF-B activity was determined using a
luciferase reporter assay. * indicates a significant difference compared with the respective control (p < 0.05). # indicates a significant difference
compared with the A431-P (p < 0.05). (H) Cellular protein levels of IBa and TG2 were detected by immunoblotting.
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IBa by the A431-III subline cells (Figures 5G &5H),
suggesting that upregulation of TG2 may induce NF-B
activity through a reduction of its inhibitor, IBa.T o
further confirm this, we used an alternative approach
whereby we transfected pcDNA3.1-TG2 into A431-P
cells. TG2 over-expressing A431-P cells exhibited a
depressed level of IBa, which was accompanied by ele-
vated NF-B activity (Figures 6A &6B). In a similar
manner to A431-III cells, treatment of TG2-overexpres-
sing A431-P cells with the NF-Bi n h i b i t o rJ S H - 2 3
reduced the level of Snail, secreted MMP-9 activity, and
migratory activity (Figures 6C to 6E). These results
together indicate that the TG2-induced acquisition of an
EMT-like phenotype by the highly invasive A431-III
cells involves the activation of NF-B signaling.
Discussion
Metastasis is a very complex and highly intriguing process.
While some of the associated molecular mechanisms have
begun to be unraveled, many remain to be understood. In
order to further reveal some of the elusive factors that
contribute to this complex process, our laboratory has
established a model system using an A431 parental tumor
cells (A431-P) and a highly invasive derivative subline
(A431-III) [25].
To date, the role of TG2 in the EMT process is not
well understood. Evidence from a limited number of
studies has revealed that TG2 localized to the cell sur-
face serves as a co-receptor for fibronectin by simulta-
neously associating with fibronectin and its receptor
integrin, mainly b1 and b3, and that this process is inde-
pendent of the catalytic activity of TG2 [36,37]. This
process may in turn promote cell adhesion, spread, and
migration [36,38]. We have further documented the
increased expression of TG2 and Snail in the A431-III
tumor subline that are both associated with the acquisi-
tion of the mesenchymal-like phenotype [26]. Addition-
ally, the upregulated expression of TG2 in A431-III cells
not only enhances the association of fibronectin with b
Figure 6 Upregulation of NF-B activity is associated with the EMT phenotype in TG2-overexpressed A431-P cells. (A) A431-P cells were
transfected with empty pcDNA3.1 vector or pcDNA3.1-TG2. Cellular protein levels of IBa and TG2 were determined at 48 h post-transfection by
immunoblotting. (B-E) Cells were treated with or without 25 μM of specific NF-B inhibitor JSH-23 for 24 h. (B) Cellular NF-B activity was
determined using a luciferase reporter assay. (C) Cellular protein levels of Snail and TG2 were detected by immunoblotting. (D) The secreted
activity of MMP-9 was analyzed by gelatin zymography. (E) Cell migratory activity was determined using a wound healing assay. Quantitative
data are presented as the mean (± SD) percentage of migration distance (n = 20). * indicates a significant difference compared with the
respective control (p < 0.05). # indicates a significant difference compared with the A431-P (p < 0.05).
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[26]. Moreover, we presented an interesting hypothesis
whereby Snail and MMP-9 form a mutual positive regu-
latory loop in highly invasive A431-III cells that may
account for the facilitation of the EMT progression [27].
The present study further shows that TG2 seems to be
able to positively regulate the expression of Snail in
A431 cells (Figures 1 &2), which suggests that TG2 may
act, at least in part, through an upregulation of Snail in
order to promote the EMT process. The molecular
mechanism of TG2 involvement in the acquisition of
the mesenchymal-like phenotype in A431-III cells still
awaits further investigation.
Previous studies have documented that the aberrant
expression of TG2 in epithelial cells results in constitu-
tive activation of focal adhesion kinase (FAK), Akt, and
NF-B [13,19,20,39]. These pathways are involved in the
regulation of the EMT, in conferring drug resistance,
and in promoting metastasis [35,40,41]. The aberrant
activation of Akt signaling is widely implicated in many
human cancers. Several studies have reported that acti-
vation of the PI3K/Akt-GSK-3b signaling pathway is
also a central feature of the EMT, and that this involves
accumulation of Snail in the nucleus [33]. As compared
to its parental cells, the highly invasive A431-III subline
displays increased Akt activity together with a concomi-
t a n tr e d u c t i o ni nG S K - 3 b activity, as well as having
increased Snail and MMP-9 levels (Figure 3). Inhibition
of PI3K activity (LY294002) in A431 tumor cells attenu-
ated the TG2-induced activation of Akt and GSK-3b,
and suppressed the increases in Snail, MMP-9, and cell
motility (Figure 4). Additionally, inhibition of GSK-3
activity (SB415286) in A431-P cells elevated the expres-
sion of Snail and MMP9, and enhanced cell motility
(Figure 4). These results support the concept that TG2
acts in part through an activation of PI3K/Akt signaling
in A431 tumor cells that inhibits GSK-3b, and therefore
upregulates Snail/MMP-9 and ultimately promotes EMT
progression. Verma et al. documented that overexpres-
sion of TG2 in cancer cells is associated with a constitu-
tive activation of focal adhesion kinase (FAK) and its
downstream PI3K/Akt pathway [16]. Our earlier study
a l s os h o w e dt h a tt h eh i g h l yi n v a s i v eA 4 3 1 - I I Is u b l i n e
exhibits increased FAK activity compared to its parental
cells [25], and that knockdown of endogenous TG2
reduced the phosphorylation activation of FAK-Tyr397
(data not shown). Collectively, these results imply that
TG2 may sequentially activate FAK and PI3K/Akt- in
A431 tumor cells, which in turn induces the acquisition
of a mesenchymal phenotype by A431 tumor cells.
Constitutive activation of NF-B is known to confer
resistance to cell death-inducing stimuli, including che-
motherapeutic agents [42], and to promote metastasis
by inducing EMT [35]. As compared to its parental
cells, the highly invasive A431-III subline has increased
NF-B activity that is largely due to a reduction of
IBa, and this has been positively associated with TG2
expression (Figures 5 &6). In addition to the increase in
TG2 level in the A431-III subline, there was also an
increased association of TG2 with p65 NF-B( F i g u r e
5). These results agree with the findings of other
researchers who have shown that drug-resistant cancer
cells have increased levels of TG2, which enhances NF-
B activity, in turn, through a novel mechanism, namely
the formation of a TG2- NF-B complex [13,15,20,43].
In this study, we also demonstrated that there was an
inhibition NF-B activity (JSH-23) in A431 tumor cells,
w h i c hl e dt oas u p p r e s s i o no ft h eT G 2 - i n d u c e d
increases in Snail, MMP-9, and cell motility (Figures 5
&6). We proposed that TG2 acts at least in part through
an activation of NF-B to upregulate Snail and MMP-9;
this then boosts the acquisition of mesenchymal charac-
teristics by the A431 tumor cells.
It is believed that cancer cells are at intermediate
states in the EMT process. Indeed, once cells have
invaded the primary tumor and penetrated the sur-
rounding tissue, they must be able to colonize at a new
tissue site. To achieve this, cancer cells may undergo a
mesenchymal-epithelial transition (MET) resulting in a
reformation of the epithelial phenotype in terms of cell-
cell adhesion [44,45]. A cancer cell that attains plasticity
and also shifts through the EMT and MET may account
for many of the difficulties associated with cancer clini-
cal therapy.
Conclusions
In a previous study, we described a rapid method to
probe, explore and learn about the EMT. As enun-
ciated elsewhere, we obtained a highly invasive A431-
III sub-line from A431-P cells via Boyden chamber
selection. Both A431-P and A431-III cells exerted
EMT characteristics, while A431-III cells have acquired
a mesenchymal-like phenotype, and also exhibit an ele-
vated expression of Snail, one of the prime factors
involved in the acquisition of the mesenchymal-like
phenotype [27]. In the present study, we have demon-
strated that the expression of Snail is associated with
enhanced NF-B and PI3K/Akt-GSK-3b and that TG2
participates in the acquisition of a mesenchymal transi-
tion. We conjecture that the enhancement of Snail
expression by TG2 induces the acquisition in A431-III
cells of a mesenchymal-like phenotype that then pro-
motes the secretion of MMP-9, which enhances cancer
cell motility and increases metastatic potential. These
observations also support our contention that that
TG2 is a promising therapeutic target for reversing
drug resistance and inhibiting the early advent of
metastasis of tumor cells.
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